Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Valent

Showing results (651-660 of 662) with videos related to

Pageof 67
Sort By:
Allergy|April 23, 2024
Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registryMarek Niedoszytko, Aleksandra Gorska, Knut Brockow, et al.
Blood Advances|May 18, 2021
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)Se Young Han, Krzysztof Mrózek, Jenna Voutsinas, et al.
Blood Advances|September 12, 2022
Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM RegistryVanessa E Kennedy, Cecelia Perkins, Andreas Reiter, et al.
Leukemia & Lymphoma|August 25, 2012
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working GroupArjan A van de Loosdrecht, Robin Ireland, Wolfgang Kern, et al.
Blood|July 3, 2024
Molecular taxonomy of myelodysplastic syndromes and its clinical implicationsElsa Bernard, Robert P Hasserjian, Peter L Greenberg, et al.
Blood|April 30, 2024
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromesMaria Sirenko, Elsa Bernard, Maria Creignou, et al.
NEJM Evidence|February 6, 2024
Molecular International Prognostic Scoring System for Myelodysplastic SyndromesElsa Bernard, Heinz Tuechler, Peter L Greenberg, et al.
Cancer Discovery|October 12, 2021
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional RespondersChristoph Kornauth, Tea Pemovska, Gregory I Vladimer, et al.
Journal of Hematology & Oncology|June 26, 2026
Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry studyOlivier Hermine, Orianne Debeaupuis, Gandhi Damaj, et al.
Nature Medicine|May 5, 2021
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromesElsa Bernard, Yasuhito Nannya, Robert P Hasserjian, et al.
Pageof 67

Showing results (651-660 of 662) with videos related to

Sort By:
Pageof 67
Allergy|April 23, 2024
Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registryMarek Niedoszytko, Aleksandra Gorska, Knut Brockow, et al.
Blood Advances|May 18, 2021
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)Se Young Han, Krzysztof Mrózek, Jenna Voutsinas, et al.
Blood Advances|September 12, 2022
Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM RegistryVanessa E Kennedy, Cecelia Perkins, Andreas Reiter, et al.
Leukemia & Lymphoma|August 25, 2012
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working GroupArjan A van de Loosdrecht, Robin Ireland, Wolfgang Kern, et al.
Blood|July 3, 2024
Molecular taxonomy of myelodysplastic syndromes and its clinical implicationsElsa Bernard, Robert P Hasserjian, Peter L Greenberg, et al.
Blood|April 30, 2024
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromesMaria Sirenko, Elsa Bernard, Maria Creignou, et al.
NEJM Evidence|February 6, 2024
Molecular International Prognostic Scoring System for Myelodysplastic SyndromesElsa Bernard, Heinz Tuechler, Peter L Greenberg, et al.
Cancer Discovery|October 12, 2021
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional RespondersChristoph Kornauth, Tea Pemovska, Gregory I Vladimer, et al.
Journal of Hematology & Oncology|June 26, 2026
Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry studyOlivier Hermine, Orianne Debeaupuis, Gandhi Damaj, et al.
Nature Medicine|May 5, 2021
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromesElsa Bernard, Yasuhito Nannya, Robert P Hasserjian, et al.
Pageof 67